A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)

NCT07073417 | Active Not Recruiting Phase 2

• 1 other identifier: SCW0502-1122
• Study Type: interventional
• Target: 163
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of the study is to compare the efficacy and safety of XW003 injection versus semaglutide injection in Chinese adults with obesity

Conditions

Obesity; Weight Management

Keywords

Weight management; obesity; XW003; glucagon-like peptide-1 (GLP-1); ecnoglutide; semaglutide

Outcome Measures

Primary Outcomes (1)

• Percentage change in body weight relative to baseline

  week 48

Secondary Outcomes (5)

• Proportions of participants with weight loss ≥5% from baseline

  week 48

• Proportions of participants with weight loss ≥10% from baseline

  week 48

• Proportions of participants with weight loss ≥15% from baseline

  week 48

• The change in waist circumference relative to the baseline

  week 48

• Changes in body mass index (BMI) relative to baseline

  week 48

Study Arms (2)

XW003

EXPERIMENTAL

once weekly

Drug: XW003 injection

semaglutide

ACTIVE COMPARATOR

once weekly

Drug: semaglutide injection

Interventions

XW003 injection DRUG

Subcutaneous injection

Also known as: ecnoglutide

XW003

semaglutide injection DRUG

Subcutaneous injection

semaglutide

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• BMI≥30 kg/m2 at screening, waist circumference ≥90 cm for men and ≥85 cm for women.
• Weight change of less than 5% within 3 months prior to screening (self-reported).

You may not qualify if:

• Diagnosis of obesity due to endocrine disorders or a single gene mutation, including but not limited to hypothalamic obesity, pituitary obesity, Cushing's syndrome, hypothyroidic obesity (except for those with normal thyroid function at screening and expected to remain unchanged throughout the trial period after at least 3 months of thyroid hormone replacement therapy), insulinoma, acromegaly.
• History of bariatric surgery or planning to undergo bariatric surgery or use other weight-loss drugs or devices during the trial (except acupuncture for weight loss, liposuction, or abdominal fat removal for more than one year before screening; Except the removal or expulsion of the airbag in the stomach for more than 1 year before screening.
• Diagnosis with any type of diabetes (except gestational diabetes).
• Have used any weight-loss drugs, hypoglycemic drugs, or drugs that may cause significant weight gain within 3 months prior to screening.
• History of acute or chronic pancreatitis or pancreatic injury, history of symptomatic gallbladder disease (except cholecystectomy).
• History of clinically significant gastric emptying abnormalities, such as gastroparesis or gastric outlet obstruction.

Sponsors & Collaborators

• Hangzhou Sciwind Biosciences Co., Ltd.: lead

Study Sites (1)

Peking University People's Hospital

Beijing, Beijing Municipality, China

Location

MeSH Terms

Conditions

Obesity

Interventions

semaglutide

Condition Hierarchy (Ancestors)

Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Linong Ji, Dr

  Peking University People's Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 9, 2025
• First Posted: July 18, 2025
• Study Start: July 28, 2025
• Primary Completion (Estimated): February 27, 2027
• Study Completion (Estimated): August 23, 2027
• Last Updated: April 13, 2026

Record last verified: 2025-07

Locations

CN (1)